Botanix Pharmaceuticals (ASX:BOT) reports it will be presenting data on catheter related bloodstream infections at the American Society of Nephrology Annual Meeting in Orlando, Florida from November 3 to 6.
The abstract entitled ‘Outcomes and Costs of Central Venous Catheter-Related S.aureus Bloodstream Infections in Hemodialysis Patients with S.aureus Nares Colonization and Diabetes Mellitus’ will be presented by author Tom Lodise on November 5 from 10am to 12pm EDT in Exhibit Hall at Orange County Convention Centre.
The company says the modelling study outlined in the abstract explored the annual cost to insurance companies associated with central venous catheter (CVC) related S.aureus bloodstream infections in CVC-hemodialysis patients with S.aureus colonisation and diabetes mellitus.
The study population for this modelling study consisted of around 45,000 patients with diabetes mellitus as the primary cause of end-stage renal disease, who start in centre CVC hemodialysis in the US each year, and the data indicates that around 18,000 of these patients with diabetes mellitus and S.aureus in their nostrils.
Botanix says among the 18,000 patients, around 9.3% of them will have a CVC related S.aureus bloodstream infection every 12 weeks, and the attributable payer costs associated with managing these infections is projected to exceed US $229 million annually.
Author Tom Lodise said the data indicates that 18,000 of the 45,000 annual incident CVC-hemodialysis patients with diabetes mellitus as primary cause of end-stage renal disease are colonised with S.aureus in their nares (nostrils).
“The annual morbidity, mortality, and healthcare costs associated with CVC-related S.aureus bloodstream infections in these patients as the primary cause of end-stage renal disease, are substantial.”
Professor of Medicine and Co-founder of Innovative Renal Care at the University of Utah Clinical and Translational Sciences Institute Jamie Dwyer said the hemodialysis patient population is highly vulnerable to infection, in particular those patients with S.aureus nares colonisation and diabetes mellitus as the primary cause of end-stage renal disease.
“The costs of treating bloodstream infections in these patients places a considerable burden on the healthcare system.
There is a need for novel therapeutics for intranasal decolonisation of S.aureus to reduce the risk of S.aureus bloodstream infections among this high-risk hemodialysis patient population with diabetes mellitus as the primary cause of ESRD.”
Botanix Pharmaceuticals is a dermatology company based in Philadelphia and Phoenix, and it is committed to the development of novel treatments for a range of common skin diseases.
The company has a mature dermatology pipeline with its first product, Sofpironium Bromide for the treatment of primary axillary hyperhidrosis filed for FDA approval in Q3 2022 with approval expected in Q3 2023.
Botanix also has a pipeline of other products in late-stage clinical dermatitis and acne, and it is also developing a topical antimicrobial product for the eradication of bacteria on the skin surface initially for patients undergoing hemodialysis.
